Literature DB >> 31748433

Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.

Saya Nagasawa1,2, Kazuhiro Ikeda1, Kuniko Horie-Inoue1, Sho Sato3, Satoru Takeda2, Kosei Hasegawa3, Satoshi Inoue1,4.   

Abstract

Ovarian cancer has the highest mortality rate among gynecological cancers. Gene mutations are involved in the carcinogenesis, metastasis, and therapeutic response in ovarian cancer. However, the variety and proportion of gene mutation is not fully analyzed in Japanese ovarian cancer patients, especially, in those with recurrent tumors. In the present study, RNA-sequencing was performed for 32 clinical ovarian specimens obtained from 24 Japanese patients (24 primary cancer specimens and 8 recurrent specimens paired with corresponding primary cancer specimens). Mutations in 24 primary specimens were analyzed by comparing the sequence data mapped on RefSeq genes with those in the public online databases BRCA Exchange, COSMIC, ClinVar, and cBioportal. Mutations were observed in TP53 in 16 specimens (67%), BRCA1 in 9 (38%), BRCA2 in 13 (54%), ARID1A in 3 (13%), PIK3CA in 2 (8%), KRAS in 1 (4%), PTEN in 1 (4%), and CTNNB1 in 1 (4%), excluding synonymous mutations. Among those identified muations, 13 of 14 mutations in TP53, 10 of 11 mutations of BRCA1, 10 of 23 mutation positions of BRCA2, none of 7 mutations of ARID1A, 1 mutation of PIK3CA, and 1 mutation of CTNNB1 were consistent with those reported in the public online databases; however, the other mutations identified were novel. Comparison between matched-paired specimens of primary and recurrent tumors revealed the changes of mutational status in expressed RNAs. RNA-sequencing-based mutation analysis will be useful to reveal ethnic differences of gene mutations in ovarian cancer and to understand the contribution of gene mutations to recurrence.

Entities:  

Keywords:  Clear cell carcinoma; High-grade serous carcinoma; Mutation; Ovarian cancer; RNA-sequencing

Mesh:

Substances:

Year:  2019        PMID: 31748433     DOI: 10.1507/endocrj.EJ19-0283

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy.

Authors:  Kosuke Murakami; Yasushi Kotani; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

2.  Long Intergenic Noncoding RNA OIN1 Promotes Ovarian Cancer Growth by Modulating Apoptosis-Related Gene Expression.

Authors:  Toshihiko Takeiwa; Yuichi Mitobe; Kazuhiro Ikeda; Kosei Hasegawa; Kuniko Horie; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

3.  From biobank and data silos into a data commons: convergence to support translational medicine.

Authors:  Rebecca Asiimwe; Stephanie Lam; Samuel Leung; Shanzhao Wang; Rachel Wan; Anna Tinker; Jessica N McAlpine; Michelle M M Woo; David G Huntsman; Aline Talhouk
Journal:  J Transl Med       Date:  2021-12-04       Impact factor: 5.531

4.  Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells.

Authors:  Saya Nagasawa; Kazuhiro Ikeda; Daisuke Shintani; Chiujung Yang; Satoru Takeda; Kosei Hasegawa; Kuniko Horie; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.